With regard to the National Strategy for Drugs for Rare Diseases: (a) since January 1, 2023, including announced commitments by all departments and agencies, what is the dollar amount that has been provided to, or committed for the purpose of provision to, the provinces and territories, through the National Strategy for Drugs for Rare Diseases, broken down by purpose; (b) for which drugs, therapies, treatments, and diseases or conditions, and what dollar amount for each type, have funds been allocated, broken down by province; (c) what funds have been directed toward providing drugs, therapies, or treatment for patients diagnosed with Pulmonary Arterial Hypertension (PAH), broken down by province; (d) what funds have been directed to the provinces and territories for drugs, therapies, and treatments relating to PAH, broken down by province; and (e) which specific drugs, therapies, or treatments have been funded for treatment of PAH?
In the House of Commons on September 16th, 2024. See this statement in context.